Pulmonary and Critical Care Considerations for e-Cigarette, or Vaping, Product Use-Associated Lung Injury.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
07 2022
Historique:
received: 29 05 2021
revised: 17 11 2021
accepted: 18 02 2022
pubmed: 9 3 2022
medline: 14 7 2022
entrez: 8 3 2022
Statut: ppublish

Résumé

In 2019, the United States experienced a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI). More than one-half of these patients required admission to an ICU. What are the recent literature and expert opinions which inform the diagnosis and management of patients with critical illness with EVALI? To synthesize information critical to pulmonary/critical care specialists in the care of patients with EVALI, this study examined data available from patients hospitalized with EVALI between August 2019 and January 2020; reviewed the clinical course and critical care experience with those patients admitted to the ICU; and compiled opinion of national experts. Of the 2,708 patients with confirmed or probable EVALI requiring hospitalization as of January 21, 2020, a total of 1,604 (59.2%) had data available on ICU admission; of these, 705 (44.0%) were admitted to the ICU and are included in this analysis. The majority of ICU patients required respiratory support (88.5%) and in severe cases required intubation (36.1%) or extracorporeal membrane oxygenation (6.7%). The majority (93.0%) of these ICU patients survived to discharge. Review of the clinical course and expert opinion provided insight into: imaging; considerations for bronchoscopy; medical treatment, including use of empiric antibiotics, antiviral agents, and corticosteroids; respiratory support, including considerations for intubation, positioning maneuvers, and extracorporeal membrane oxygenation; and patient outcomes. Review of the clinical course of patients with EVALI requiring ICU admission and compilation of expert opinion provided critical insight into pulmonary/critical care-specific considerations for this patient population. Because a large proportion of patients hospitalized with EVALI required ICU admission, it is important to remain prepared to care for patients with EVALI.

Sections du résumé

BACKGROUND
In 2019, the United States experienced a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI). More than one-half of these patients required admission to an ICU.
RESEARCH QUESTION
What are the recent literature and expert opinions which inform the diagnosis and management of patients with critical illness with EVALI?
STUDY DESIGN AND METHODS
To synthesize information critical to pulmonary/critical care specialists in the care of patients with EVALI, this study examined data available from patients hospitalized with EVALI between August 2019 and January 2020; reviewed the clinical course and critical care experience with those patients admitted to the ICU; and compiled opinion of national experts.
RESULTS
Of the 2,708 patients with confirmed or probable EVALI requiring hospitalization as of January 21, 2020, a total of 1,604 (59.2%) had data available on ICU admission; of these, 705 (44.0%) were admitted to the ICU and are included in this analysis. The majority of ICU patients required respiratory support (88.5%) and in severe cases required intubation (36.1%) or extracorporeal membrane oxygenation (6.7%). The majority (93.0%) of these ICU patients survived to discharge. Review of the clinical course and expert opinion provided insight into: imaging; considerations for bronchoscopy; medical treatment, including use of empiric antibiotics, antiviral agents, and corticosteroids; respiratory support, including considerations for intubation, positioning maneuvers, and extracorporeal membrane oxygenation; and patient outcomes.
INTERPRETATION
Review of the clinical course of patients with EVALI requiring ICU admission and compilation of expert opinion provided critical insight into pulmonary/critical care-specific considerations for this patient population. Because a large proportion of patients hospitalized with EVALI required ICU admission, it is important to remain prepared to care for patients with EVALI.

Identifiants

pubmed: 35257738
pii: S0012-3692(22)00406-8
doi: 10.1016/j.chest.2022.02.039
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

256-264

Informations de copyright

Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Don Hayes (D)

Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: Don.Hayes@cchmc.org.

Amy Board (A)

Epidemic Intelligence Service, National Center for Injury Prevention and Control, Atlanta, GA.

Carolyn S Calfee (CS)

University of California at San Francisco School of Medicine, San Francisco, CA.

Sascha Ellington (S)

Centers for Disease Control and Prevention, Atlanta, GA.

Lori A Pollack (LA)

Centers for Disease Control and Prevention, Atlanta, GA.

Hasmeena Kathuria (H)

Boston University Medical Center, Boston, MA.

Michelle N Eakin (MN)

Johns Hopkins University School of Medicine, Baltimore, MD.

David N Weissman (DN)

Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, WV.

Sean J Callahan (SJ)

University of Utah School of Medicine, Salt Lake City, UT.

Annette M Esper (AM)

Emory University School of Medicine, Atlanta, GA.

Laura E Crotty Alexander (LE)

University of California at San Diego School of Medicine, San Diego, CA.

Nirmal S Sharma (NS)

Brigham and Women's Hospital, Boston, MA.

Nuala J Meyer (NJ)

University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Lincoln S Smith (LS)

Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA.

Shannon Novosad (S)

Centers for Disease Control and Prevention, Atlanta, GA.

Mary E Evans (ME)

Centers for Disease Control and Prevention, Atlanta, GA.

Alyson B Goodman (AB)

Centers for Disease Control and Prevention, Atlanta, GA.

Eleanor S Click (ES)

Centers for Disease Control and Prevention, Atlanta, GA.

Richard T Robinson (RT)

The Ohio State University College of Medicine, Columbus, OH.

Gary Ewart (G)

American Thoracic Society, New York, NY.

Evelyn Twentyman (E)

Centers for Disease Control and Prevention, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH